Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer
Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success Dr. Dube succeeds Stephen Aselage , who will continue serving on Board SAN DIEGO , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of
View HTML
Toggle Summary Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage , chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 11:00 a.m. PT ( 2:00 p.m. ET ).
View HTML
Toggle Summary Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
SAN DIEGO , Dec. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy
View HTML
Toggle Summary Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN
Top-line data anticipated in the third quarter of 2019 SAN DIEGO , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and efficacy of fosmetpantotenate for the treatment
View HTML
Toggle Summary Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference
SAN DIEGO , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage , chief executive officer, will present at the BMO 2018 Prescriptions for Success Healthcare Conference in New York City on Wednesday, December 12, 2018 at 9:20 a.m. ET .
View HTML
Toggle Summary Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
PDUFA date set for June 30, 2019 SAN DIEGO , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review the New Drug Application (NDA) for a new formulation of Thiola (tiopronin) in the treatment of
View HTML
Toggle Summary Retrophin to Present at the Jefferies 2018 London Healthcare Conference
SAN DIEGO , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 4:40 p.m. GMT ( 11:40 a.m. ET ).
View HTML
Toggle Summary Retrophin Reports Third Quarter 2018 Financial Results
Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million convertible senior notes due 2025 SAN DIEGO, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced new positive data from the ongoing
View HTML
Toggle Summary Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018 SAN DIEGO , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Journal of the American Society of Nephrology (JASN) has published online (doi: 10.1681/ASN.2018010091 ) the
View HTML